|Dr. Robert E. Dudley Ph.D.||Founder, Pres, CEO & Director||557.6k||N/A||1955|
|Mr. Steven A. Bourne CPA||Chief Admin. Officer & Sec.||410.83k||N/A||1962|
|Mr. Frank A. Jaeger M.A., M.B.A.||Chief Commercial Officer||414.23k||N/A||1970|
|Mr. Richard Dale Peterson||Chief Financial Officer||N/A||N/A||1968|
|Mr. Steve Stark||VP of Commercial Analytics & Operations||N/A||N/A||N/A|
|Ms. Kara J. Stancell||VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Ms. LaTonya Wright||VP of Sales||N/A||N/A||N/A|
|Ms. Rozita Passarella||VP of Marketing||N/A||N/A||N/A|
|Dr. Jay Newmark M.B.A., M.D.||Chief Medical Officer||N/A||N/A||N/A|
|Mr. James Holloway||Sr. VP of Manufacturing & Supply||N/A||N/A||N/A|
Clarus Therapeutics Holdings, Inc. operates as a men's health specialty pharmaceutical company that focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen-dependent inflammatory breast disease and certain forms of breast cancer. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.
Clarus Therapeutics Holdings, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.